Syngene International invests in peptide laboratory in Bengaluru
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
Accelerating hit-to-lead timelines, and strengthening end-to-end drug discovery and development services
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Subscribe To Our Newsletter & Stay Updated